









Markets
/
Stocks
/
nasdaq-phvs
/

Pharvaris NV

PHVS

View Detailed Chart

25.120USD

+5.290+26.68%

Close 07/11, 16:00（ET）Quotes delayed by 15 min

1.37BMarket Cap

LossP/E TTM



Pharvaris NV

25.120

+5.290+26.68%

Overview Company Financials

Financials

Intraday

30m

Today

+26.68%

5 Days

+35.05%

1 Month

+47.33%

6 Months

+41.12%

Year to Date

+31.04%

1 Year

+37.72%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 11 analysts

BUY

Current Rating

33.091

Target Price

66.87%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

556

Total

Median

Average

Company name

Ratings

Analysts

Pharvaris NV

PHVS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(0)

Buy(8)

Indicators

Sell(1)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

1.097

Buy

RSI(14)

79.902

Buy

STOCH(KDJ)(9,3,3)

88.986

Overbought

ATR(14)

1.452

High Vlolatility

CCI(14)

387.104

Overbought

Williams %R

7.080

Overbought

TRIX(12,20)

0.524

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

19.886

Buy

MA10

18.770

Buy

MA20

17.993

Buy

MA50

17.328

Buy

MA100

16.265

Buy

MA200

17.971

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Ticker SymbolPHVS

CompanyPharvaris NV

CEOMr. Berndt Modig, CPA

Websitehttps://pharvaris.com/